ESMO 2026 SYMPOSIUM
SCLC
SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era
A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.
Therapy Areas
Drug Classes
Therapy Areas
All Sessions
Resectable NSCLC
Advanced NSCLC
SCLC
Biomarkers
Drug Classes
Targeted Therapies
Immunotherapies
ADCs
All
FEATURED
ILCS
Webinars
Articles
Industry Sponsored
Featured Sessions
Oct252026
M. ReckS. PetersG. MountziosN. Reguart
Jul
20
2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies
Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi
Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.
O. Gautschi
May
04
2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies
Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro
Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.
A. Curioni-Fontecedro
Sep
26
2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies
Latest Advances in Frontline EGFR+ NSCLC
14 min
A. Curioni-Fontecedro
Sep
26
2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies
Unlocking New Potentials in EGFR-Mutant NSCLC
30 min
A. Passaro
Oct
05
2024
INDUSTRY SYMPOSIUM
Advanced NSCLCADCs
Best Practices in Managing Adverse Events with ADCs in NSCLC
18 min
N. Girard
From Our Annual Summit
ILCS Sessions
Nov132026
ILCS 2026
The International Lung Cancer Summit 2026
Learn more about the event
S. PetersA. AddeoM. DasH. HorinouchiT. SequeiraC. LovlyD. PlanchardS. PatelA. CortelliniN. FrostG. MountziosA. Dingemans
Sep
26
2025
ILCS 2025
SCLC
Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease
34 min
R. Manochakian
Sep
26
2025
ILCS 2025
Advanced NSCLC
Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond
32 min
A. Curioni-Fontecedro
Sep
26
2025
ILCS 2025
Immunotherapies
The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC
28 min
A. Filippi
Sep
26
2025
ILCS 2025
Immunotherapies
Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes
36 min
P. Forde
Sep
26
2025
ILCS 2025
ADCs
The ADC Revolution in Lung Cancer: New Targets, New Opportunities
27 min
N. Reguart
Sep
26
2025
ILCS 2025
Targeted Therapies
DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?
31 min
T. Newsom-DavisX. Le
Sep
26
2025
ILCS 2025
Targeted Therapies
Actionable Genomic Alterations – Including HER2 and MET
26 min
S. Saw
Expert Insights
Webinars
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs
2026 Year in Review
Learn more about the event
S. PetersJ. SandsM. Reck
Dec
18
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs
2025 Approvals & Highlights
1 h 49 min
S. PetersC. RudinM. Reck
Jul
10
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies
Targeted Therapies in NSCLC
1h 30 min
O. GautschiJ. NaidooN. Girard
Jun
25
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCImmunotherapies
Immunotherapies in NSCLC
1h 47 min
P. FordeJ. RemonS. Peters
Jun
17
2025
VIRTUAL ROUNDTABLE
SCLCImmunotherapies
Small Cell Lung Cancer
1h 35 min
G. MountziosJ. SandsS. Peters
The Reading Room
Articles & Research
Oct
30
2026
RESEARCH
SCLCImmunotherapies
Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up
C. RudinG. Mountzios
Oct
30
2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies
Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial
M. ReckN. GirardA. Filippi
Oct
29
2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies
Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2
T. CasconeP. Forde
Oct
29
2026
RESEARCH
Advanced NSCLCImmunotherapies
Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE
M. Pérol
Oct
27
2026
RESEARCH
SCLCImmunotherapies
Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC
J. SandsM. PérolA. Dingemans
Oct
26
2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies
Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC
Oct
23
2026
RESEARCH
SCLCImmunotherapies
KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC
J. SandsM. Reck
Oct
22
2026
RESEARCH
Advanced NSCLC
TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients
R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct
21
2026
SPONSORED
Advanced NSCLCImmunotherapies
The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC
A. Curioni-Fontecedro
Oct
21
2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC
ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational
U. Malapelle
Oct
19
2026
RESEARCH
Advanced NSCLCImmunotherapies
Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update
H. Horinouchi
Oct
18
2026
RESEARCH
Advanced NSCLCTargeted Therapies
First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg
X. LeD. PlanchardM. Pérol
Oct
17
2026
RESEARCH
Community indicators flagged high lung cancer incidence areas in California better than smoking alone
S. Patel
Oct
16
2026
RESEARCH
Advanced NSCLCTargeted Therapies
Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months
A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct
16
2026
RESEARCH
Advanced NSCLC
Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study
L. Bubendorf
Oct
15
2026
NEWS
Resectable NSCLC
A papal diagnosis turns the world’s attention to its most diagnosed cancer
Oct
14
2026
RESEARCH
Advanced NSCLCTargeted Therapies
Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue
N. Girard
Oct
14
2026
RESEARCH
Resectable NSCLC
More lymph nodes examined at segmentectomy tracked with longer survival in early-stage NSCLC
J. Perentes
Oct
08
2026
RESEARCH
Advanced NSCLCTargeted Therapies
Amivantamab, lazertinib and bevacizumab gave a 33% response rate after osimertinib in AMAZE-lung
R. StahelM. PérolA. AddeoS. Peters
Oct
07
2026
RESEARCH
BiomarkersSCLC
IASLC pathologists propose a grade 3 category for lung carcinoids with more than 10 mitoses
P. Hofman
Industry Sponsored
Featured Sessions
Oct252026
ESMO 2026 SYMPOSIUM
SCLC
SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era
A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.
M. ReckS. PetersG. MountziosN. Reguart
Jul
20
2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies
Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi
Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.
O. Gautschi
May
04
2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies
Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro
Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.
A. Curioni-Fontecedro
Sep
26
2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies
Latest Advances in Frontline EGFR+ NSCLC
14 min
A. Curioni-Fontecedro
Sep
26
2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies
Unlocking New Potentials in EGFR-Mutant NSCLC
30 min
A. Passaro
Oct
05
2024
INDUSTRY SYMPOSIUM
Advanced NSCLCADCs
Best Practices in Managing Adverse Events with ADCs in NSCLC
18 min
N. Girard
From Our Annual Summit
ILCS Sessions
Nov132026
ILCS 2026
The International Lung Cancer Summit 2026
Learn more about the event
S. PetersA. AddeoM. DasH. HorinouchiT. SequeiraC. LovlyD. PlanchardS. PatelA. CortelliniN. FrostG. MountziosA. Dingemans
Sep
26
2025
ILCS 2025
SCLC
Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease
34 min
R. Manochakian
Sep
26
2025
ILCS 2025
Advanced NSCLC
Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond
32 min
A. Curioni-Fontecedro
Sep
26
2025
ILCS 2025
Immunotherapies
The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC
28 min
A. Filippi
Sep
26
2025
ILCS 2025
Immunotherapies
Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes
36 min
P. Forde
Sep
26
2025
ILCS 2025
ADCs
The ADC Revolution in Lung Cancer: New Targets, New Opportunities
27 min
N. Reguart
Sep
26
2025
ILCS 2025
Targeted Therapies
DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?
31 min
T. Newsom-DavisX. Le
Sep
26
2025
ILCS 2025
Targeted Therapies
Actionable Genomic Alterations – Including HER2 and MET
26 min
S. Saw
Expert Insights
Webinars
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs
2026 Year in Review
Learn more about the event
S. PetersJ. SandsM. Reck
Dec
18
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs
2025 Approvals & Highlights
1 h 49 min
S. PetersC. RudinM. Reck
Jul
10
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies
Targeted Therapies in NSCLC
1h 30 min
O. GautschiJ. NaidooN. Girard
Jun
25
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCImmunotherapies
Immunotherapies in NSCLC
1h 47 min
P. FordeJ. RemonS. Peters
Jun
17
2025
VIRTUAL ROUNDTABLE
SCLCImmunotherapies
Small Cell Lung Cancer
1h 35 min
G. MountziosJ. SandsS. Peters
The Reading Room
Articles & Research
Oct
30
2026
RESEARCH
SCLCImmunotherapies
Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up
C. RudinG. Mountzios
Oct
30
2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies
Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial
M. ReckN. GirardA. Filippi
Oct
29
2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies
Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2
T. CasconeP. Forde
Oct
29
2026
RESEARCH
Advanced NSCLCImmunotherapies
Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE
M. Pérol
Oct
27
2026
RESEARCH
SCLCImmunotherapies
Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC
J. SandsM. PérolA. Dingemans
Oct
26
2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies
Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC
Oct
23
2026
RESEARCH
SCLCImmunotherapies
KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC
J. SandsM. Reck
Oct
22
2026
RESEARCH
Advanced NSCLC
TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients
R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct
21
2026
SPONSORED
Advanced NSCLCImmunotherapies
The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC
A. Curioni-Fontecedro
Oct
21
2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC
ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational
U. Malapelle
Oct
19
2026
RESEARCH
Advanced NSCLCImmunotherapies
Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update
H. Horinouchi
Oct
18
2026
RESEARCH
Advanced NSCLCTargeted Therapies
First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg
X. LeD. PlanchardM. Pérol
Oct
17
2026
RESEARCH
Community indicators flagged high lung cancer incidence areas in California better than smoking alone
S. Patel
Oct
16
2026
RESEARCH
Advanced NSCLCTargeted Therapies
Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months
A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct
16
2026
RESEARCH
Advanced NSCLC
Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study
L. Bubendorf
Oct
15
2026
NEWS
Resectable NSCLC
A papal diagnosis turns the world’s attention to its most diagnosed cancer
Oct
14
2026
RESEARCH
Advanced NSCLCTargeted Therapies
Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue
N. Girard
Oct
14
2026
RESEARCH
Resectable NSCLC
More lymph nodes examined at segmentectomy tracked with longer survival in early-stage NSCLC
J. Perentes
Oct
08
2026
RESEARCH
Advanced NSCLCTargeted Therapies
Amivantamab, lazertinib and bevacizumab gave a 33% response rate after osimertinib in AMAZE-lung
R. StahelM. PérolA. AddeoS. Peters
Oct
07
2026
RESEARCH
BiomarkersSCLC
IASLC pathologists propose a grade 3 category for lung carcinoids with more than 10 mitoses
P. Hofman
Oct
06
2026
RESEARCH
Four Austrian societies back a national, risk-adapted lung cancer screening programme
M. Hochmair
Oct
06
2026
RESEARCH
Advanced NSCLCImmunotherapies
Two-thirds of patients with PD-L1-high NSCLC received first-line immunotherapy alone in a real-world survey
D. Rodríguez-Abreu
Oct
05
2026
RESEARCH
Advanced NSCLCTargeted Therapies
A JCO review sets PACC mutations and exon 20 insertions apart from classical EGFR mutations in NSCLC
A. AddeoX. Le
Oct
05
2026
RESEARCH
SCLCImmunotherapies
Second-line therapy in ES-SCLC gave a median OS of 7.1 months in the Austrian LALUCA registry
M. Hochmair
Oct
04
2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies
Checkpoint inhibitors were associated with longer survival in NSCLC after allogeneic stem cell transplantation
N. FrostM. ReckA. Cortellini
Oct
04
2026
RESEARCH
SCLCImmunotherapies
Longer OS in Asian than non-Asian patients given atezolizumab plus chemotherapy for extensive-stage SCLC
S. LiuM. ReckC. Rudin
Oct
03
2026
RESEARCH
Advanced NSCLCResectable NSCLCTargeted Therapies
AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy
A. Calles
Oct
03
2026
RESEARCH
Advanced NSCLCTargeted Therapies
KRAS inhibitors in NSCLC: modest survival gains, inevitable resistance and combinations in early trials
V. Noronha
Oct
02
2026
RESEARCH
Advanced NSCLCTargeted Therapies
Sutetinib produced responses in 71% of patients with uncommon EGFR mutations in a phase IIb trial
X. Le
Oct
02
2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies
High tumour mutational burden was associated with more frequent and earlier immune-related adverse events in advanced NSCLC
B. Ricciuti
Oct
01
2026
RESEARCH
Advanced NSCLCTargeted Therapies
Uncommon EGFR exon 19 deletions were associated with shorter PFS on osimertinib in a 111-patient study
H. Horinouchi
Oct
01
2026
RESEARCH
Targeted Therapies
RAS alterations drove resistance in about one in ten oncogene-driven lung cancers progressing on targeted therapy
B. RicciutiJ. RemonD. Planchard
Sep
30
2026
RESEARCH
Advanced NSCLCSCLCADCs
Pulmonary adverse events affected almost a third of lung cancer patients treated with ADCs in a 24-study meta-analysis
C. Rolfo
Sep
30
2026
RESEARCH
Resectable NSCLC
Spread through air spaces predicted relapse after both lobectomy and segmentectomy in JCOG0802 stage IA NSCLC
S. BerezowskaL. BubendorfP. Hofman
Sep
28
2026
RESEARCH
Resectable NSCLCImmunotherapies
AEGEAN’s second interim analysis kept the EFS benefit of perioperative durvalumab, on an OS reading that crosses 1
M. ReckM. Hochmair
Sep
26
2026
RESEARCH
Advanced NSCLCImmunotherapies
Incidental thymic radiation dose was independently associated with metastasis and death in 1107 patients with NSCLC
B. Ricciuti
Sep
25
2026
RESEARCH
Resectable NSCLCTargeted Therapies
Multi-omic profiling separated recurrence risk within pathological stage in resected EGFR-mutant lung adenocarcinoma
S. Saw
Sep
23
2026
CONGRESS
Advanced NSCLCTargeted Therapies
Zidesamtinib produced responses in 94% of ROS1 TKI-naive patients in ARROS-1
Sep
19
2026
RESEARCH
Resectable NSCLC
Spread through air spaces carried an HR of 2.32 for DFS in stage 1 lung adenocarcinoma
S. Saw
Sep
18
2026
INDUSTRY NEWS
Advanced NSCLCTargeted Therapies